NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.20
-0.15 (-1.60%)
At close: Dec 5, 2025, 4:00 PM EST
9.17
-0.03 (-0.33%)
After-hours: Dec 5, 2025, 4:04 PM EST
Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors.
The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.
NeOnc Technologies Holdings, Inc.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Amir Heshmatpour |
Contact Details
Address: 23975 Park Sorrento, Suite 205 Calabasas, California 91302 United States | |
| Phone | 310-663-7831 |
| Website | neonc.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| CUSIP Number | 64051A101 |
| ISIN Number | US64051A1016 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amir Farrokh Heshmatpour | President, Chief Executive Officer, Executive Chairman and Secretary |
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer and Vice Chairman |
| Keithly A. Garnett | Chief Financial Officer |
| Dr. Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 424B4 | Prospectus |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 8-K | Current Report |
| Oct 30, 2025 | 8-K | Current Report |
| Oct 10, 2025 | 8-K | Current Report |
| Oct 9, 2025 | 8-K | Current Report |